DYNAMICS OF TNF, IFNG AND IL6 GENE EXPRESSION IN CHRONIC MYELOID LEUKAEMIA PATIENTS ON IMATINIB TREATMENTYESICA

FERRI CRISTIAN; LARRIPA IRENE; BESTACH YESICA; BELLI CAROLINA

Miami (USA)

Congreso; 20TH ANNUAL JOHN GOLDMAN CONFERENCE ON CML: BIOLOGY AND THERAPY; 2018

European School of Hematology

Imatinib remains as the preferred tyrosine kinase inhibitor (TKI) therapy for chronic myeloid leukaemia (CML) patients. Besides its direct action targeting BCR-ABL1, TKI therapy may also influence the anti-tumour response. A limiting anti-CML immune response has been described at diagnosis, while on TKI treatment, the immune system seems to re-activate. Previous papers about this topic are very heterogeneous, and longitudinal follow up studies are scarce or missing. Our aim was to analyse the dynamic of TNF, IFNG and IL6 gene expression regarding molecular response to Imatinib, since there are no previous articles focused on addressing this issue on the same sample used to monitor %BCR-ABL1/ABL1.This study included 161 peripheral blood samples from 92 CML patients who were analysed according to the molecular response at each time point. In accordance with a basal immune suppression, the expression of TNF, IFNG and IL6 was significantly diminished at diagnosis when compared with healthy controls (N=26) (p=0.0336, p